Streptococcus pneumoniae type 8 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 8 of Streptococcus pneumoniae. It is an active immunization... It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- First approval
- Canada, 2005 · United States, 1983 · European Union, 2022
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 8 capsular polysaccharide antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account